Haemonetics Corporation (HAE) Q4 2025 Earnings Report

Haemonetics Corporation (HAE) reported robust financial performance in Q4 2025, delivering total revenue of $1.4 billion, representing a 4% growth year-over-year and a promising organic growth of 8% when excluding the impacts of the CSL divestiture and Whole Blood divestiture. This performance is attributed significantly to the hospital segment, now the largest business area, alongside significant recovery and margin expansion in the Plasma business. Management highlighted strong cash flow generation, with free cash flow growing 24% annually, underpinned by strategic initiatives aimed at optimizing the company's growth trajectory in the healthcare sector. Share buybacks totaling $150 million demonstrate confidence in future value creation and solidify the company's commitment to enhancing shareholder returns.